Dariusz Pytel to Protein Kinase Inhibitors
This is a "connection" page, showing publications Dariusz Pytel has written about Protein Kinase Inhibitors.
Connection Strength
1.027
-
Tyrosine kinase blockers: new hope for successful cancer therapy. Anticancer Agents Med Chem. 2009 Jan; 9(1):66-76.
Score: 0.276
-
The Potential Role of Small-Molecule PERK Inhibitor LDN-0060609 in Primary Open-Angle Glaucoma Treatment. Int J Mol Sci. 2021 Apr 26; 22(9).
Score: 0.162
-
The PERK-Dependent Molecular Mechanisms as a Novel Therapeutic Target for Neurodegenerative Diseases. Int J Mol Sci. 2020 Mar 19; 21(6).
Score: 0.150
-
Potential therapeutic application of PERK inhibitors Postepy Biochem. 2019 06 06; 65(2):118-127.
Score: 0.142
-
Breaking the DNA Damage Response via Serine/Threonine Kinase Inhibitors to Improve Cancer Treatment. Curr Med Chem. 2019; 26(8):1425-1445.
Score: 0.138
-
Unfolded Protein Response and PERK Kinase as a New Therapeutic Target in the Pathogenesis of Alzheimer's Disease. Curr Med Chem. 2015; 22(27):3169-84.
Score: 0.104
-
Imatinib mesylate (STI571) abrogates the resistance to doxorubicin in human K562 chronic myeloid leukemia cells by inhibition of BCR/ABL kinase-mediated DNA repair. Mutat Res. 2006 Jan 31; 603(1):74-82.
Score: 0.056